Product Revenue, Net was Ocular Therapeutix’s largest product and service line in fiscal 2025, bringing in $51.82M of $51.95M (100%).
| Product and Service | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue, Net | $50.46M | $57.87M | $63.46M | $51.82M | |||||||||||
| Product | — | — | — | — | |||||||||||
| Collaboration Revenue | $1.04M | $573.00K | $262.00K | $128.00K | |||||||||||
| Total | $51.49M | $58.44M | $63.72M | $51.95M |
Ocular Therapeutix brought in $51.95M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 18.5% from $63.72M in fiscal 2024. Product Revenue, Net was the largest at $51.82M (99.8%), ahead of Collaboration Revenue at $128.00K (0.2%).
From fiscal 2022 to 2025, combined revenue from these lines grew from $51.49M to $51.95M, a compound annual growth rate of 0.3%. Product Revenue, Net's share of the total rose from 98.0% to 99.8%.
Ocular Therapeutix (OCUL) reports its revenue by product and service. In fiscal 2025, Product Revenue, Net was its largest product and service line, bringing in $51.82M (99.8% of the total), followed by Collaboration Revenue at $128.00K (0.2%).
Product Revenue, Net was Ocular Therapeutix's largest product and service line in fiscal 2025, bringing in $51.82M, or 99.8% of the $51.95M total across its two product and service lines.
Every figure comes from Ocular Therapeutix's annual financial filings, as reported. Each line keeps the name Ocular Therapeutix gives it, and years follow its fiscal calendar.
Ocular Therapeutix's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.